Myriad Genetics | MYGN - Ebitda

Stock Price
3.58
Daily Change
-0.04 -1.11%
Monthly
-28.40%
Yearly
-13.32%
Q2 Forecast
3.51

Myriad Genetics reported $14.3M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agilent USD 540M 74M Sep/2025
Becton, Dickinson and Co. USD 1.71B 433M Dec/2025
Bio-Rad Laboratories USD 983.8M 1.36B Dec/2025
Bruker USD 110M 101.6M Mar/2026
Danaher USD 1.92B 204M Mar/2026
Illumina USD 469M 137M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Mettler Toledo International USD 278.99M 100.24M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Quest Diagnostics USD 557M 20M Mar/2026
Quidel USD 108.7M 44.6M Mar/2026
Repligen USD 40.01M 469K Mar/2026
Revvity USD 272.91M 24M Mar/2026
Standard Biotools USD -15.81M 734K Dec/2025
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
Veracyte USD 42.8M 488K Mar/2026
Waters USD 380.97M 85.83M Dec/2025